Abstract
The authors regret that the following errors occurred in following subsections. Changes can be found in italics below: 2.6. Pharmacokinetic (PK)assessment in humanized mice Further, all mice in ARV NPs and ARV solution treatment group, received subcutaneously (SubQ)TAF+FTC NPs and TAF+FTC along with elvitegavir (EVG)in solution (at 200 mg/kg each drug), respectively. However, EVG is not related to present study, has no drug-drug interactions [1]and a complete PK study related to EVG has been previously published. Hence, EVG has not been discussed any further in the present article [2,3]. 2.9. Ethics statement Last sentence: All PK in vivo experiments (except the group of mice that received drugs in solution)were performed in accordance with Creighton University IACUC approved protocol (Protocol #0989). References [1]AIDSinfo, Drug Interactions between Nucleoside Reverse Transcriptase Inhibitors and Other Drugs (Including Antiretroviral Agents). in: U.S.D.o.H.H. Services (Ed.), U.S. Department of Health & Human Services, Washington, DC, USA, 2018. [2]P.K. Prathipati, S. Mandal, G. Pon, R. Vivekanandan, C.J. Destache, Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model, Pharm Res, 34 (2017)2749-2755. [3]S. Mandal, P.K. Prathipati, G. Kang, Y. Zhou, Z. Yuan, W. Fan, Q. Li, C.J. Destache, Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission, AIDS, 31 (2017)469-476. The authors would like to apologise for any inconvenience caused.